Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,457 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 1,457 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel owned 18,086 shares of the company’s stock, valued at $541,675.70. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock traded up $0.74 during trading hours on Thursday, reaching $31.00. The company’s stock had a trading volume of 1,946,301 shares, compared to its average volume of 698,331. The firm has a 50 day moving average price of $32.07 and a 200-day moving average price of $32.35. Stoke Therapeutics, Inc. has a one year low of $11.17 and a one year high of $40.22. The stock has a market cap of $1.93 billion, a P/E ratio of -11.03 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The firm had revenue of $6.23 million for the quarter, compared to analysts’ expectations of $6.48 million. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -3.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Wedbush lifted their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Needham & Company LLC increased their price target on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Canaccord Genuity Group raised their price target on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Finally, Wolfe Research started coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.83.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new stake in shares of Stoke Therapeutics during the fourth quarter valued at $26,000. KBC Group NV purchased a new position in Stoke Therapeutics in the 1st quarter worth about $36,000. Harbour Investments Inc. lifted its holdings in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares in the last quarter. Western Wealth Management LLC bought a new stake in Stoke Therapeutics during the 1st quarter valued at about $55,000. Finally, Generali Investments Management Co LLC purchased a new stake in Stoke Therapeutics in the 3rd quarter valued at about $41,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.